Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia.

作者: Irawan Yusuf , Meta W. Djojosubroto , Risma Ikawati , Koji Lum , Akira Kaneko

DOI: 10.1007/978-1-4615-0059-9_3

关键词:

摘要: The genetic polymorphism of drug-metabolizing enzymes has a major influence on the fate xenobiotic substances, whether as drugs or absorbed from environment. Our understanding this is important in order to evaluate predisposition for exposure-related risks and, future, develop individualized drug therapy. Cytochrome P450 play central role metabolism many drugs, chemicals, and carcinogens. Differences activity these are responsible inter-individual variability response toxicity (Bertilsson, 1995). Of cytochrome enzymes, isoform CYP2C19 particular interest because its high inter-racial differences (Goldstein et al., 1997; Kaneko 1999; Griese 2001).

参考文章(38)
X QIN, H XIE, W WANG, N HE, S HUANG, Z XU, D OUYANG, Y WANG, H ZHOU, Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects Clinical Pharmacology & Therapeutics. ,vol. 66, pp. 642- 646 ,(1999) , 10.1053/CP.1999.V66.103379001
S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, J.A. Goldstein, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry. ,vol. 269, pp. 15419- 15422 ,(1994) , 10.1016/S0021-9258(17)40694-6
J. M. Roberts-Thomson, B. Boettcher, J. B. Clegg, J. J. Martinson, J. T. Norwich, R. M. Harding, An ancient common origin of aboriginal Australians and New Guinea highlanders is supported by alpha-globin haplotype analysis. American Journal of Human Genetics. ,vol. 58, pp. 1017- 1024 ,(1996)
Christine Bouchardy, Simone Benhamou, Joyce A. Goldstein, Joyce Blaisdell, Urs Meyer, Pierre Dayer, Burhan I. Ghanayem, Gordon C. Ibeanu, Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin Journal of Pharmacology and Experimental Therapeutics. ,vol. 286, pp. 1490- 1495 ,(1998)
Joyce A. Goldstein, Zhou-Sheng Xiao, Joyce Blaisdell, Nan He, Song-Ling Huang, Hong-Guang Xie, Wei Wang, Chang-Hong Jiang, Feng-Xiang Yan, Zhen-Hua Xu, Hong-Hao Zhou, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics. ,vol. 281, pp. 604- 609 ,(1997)
C. Bouchardy, S. Benhamou, J. A. Goldstein, J. Blaisdell, J. M. Wright, T. C. Sarich, P. Dayer, G. R. Wilkinson, G. Ibeanu, S. M. F. De Morais, R. J. Ferguson, A New Genetic Defect in Human CYP2C19: Mutation of the Initiation Codon Is Responsible for Poor Metabolism of S-Mephenytoin Journal of Pharmacology and Experimental Therapeutics. ,vol. 284, pp. 356- 361 ,(1998)
K Brøsen, P Beaune, K K Nielsen, J P Flinois, The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. Journal of Pharmacology and Experimental Therapeutics. ,vol. 277, pp. 1659- 1664 ,(1996)
Miyuki Kimura, Ichiro Ieiri, Kohsuke Mamiya, Akinori Urae, Shun Higuchi, Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population Therapeutic Drug Monitoring. ,vol. 20, pp. 243- 247 ,(1998) , 10.1097/00007691-199806000-00001
Toshio Yasumori, Li Qing-Hua, Yasushi Yamazoe, Toshiharu Tsuzuki, Ryuichi Kato, Masakazu Ueda, Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. Pharmacogenetics. ,vol. 4, pp. 323- 331 ,(1994) , 10.1097/00008571-199412000-00005